NEW DRUGS AND FUTURE-DEVELOPMENTS IN PHOTODYNAMIC THERAPY

New photosensitising drugs are becoming available which should improve on some of the disadvantages of haematoporphyrin derivates for photod ynamic therapy (PDT). The main features are shorter duration of system ic photosensitisation, activation by longer and more penetrating tight and better tumour to normal tissue drug uptake ratios. These drugs to gether with better understanding of in vivo light dosimetry promise to improve both results and clinical acceptability for PDT in future stu dies.